These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.
What does FDA’s record show, in brief?
| Facility | Pine Pharmaceuticals, LLC |
| Location | Tonawanda, New York |
| Type | 503B outsourcing facility |
| Registered since | March 9, 2018 |
| Latest registration | October 9, 2026 |
| Last FDA inspection | November 14, 2025 |
| Inspection dates | 11/4/2025 to 11/14/2025 |
| Form 483 | Issued, 4 observations |
| FDA action after the inspection | Warning Letter Issued 8/7/202 |
| Compounds sterile drugs from bulk | Yes |
| FDA warning letters on GLP-1 drugs | 0 |
What did FDA’s investigators observe?
The Form 483 from the inspection of 11/14/2025 lists 4 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2
| What the observation is about | Observations |
|---|---|
| Sterility and aseptic processing | 1 |
| Written procedures and quality unit | 1 |
| Environmental and personnel monitoring | 1 |
FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.
Has this facility recalled any drugs?
FDA’s enforcement reports list 24 recalled products from this facility, from November 4, 2015 to October 2, 2023: 22 in Class II, 2 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2023-10-02 | II | Lidocaine-phenylephrine 1%-1.5% 1mL Single Dose Vial | Lack of Assurance of Sterility |
| 2023-10-02 | II | Cefuroxime 4mg /0.4 mL (10 mg/mL) | Lack of Assurance of Sterility |
| 2023-10-02 | II | Moxifloxacin in Balanced Salt Solution 400 mcg/0.4 mL (100 mcg/0.1 mL) | Lack of Assurance of Sterility |
| 2023-10-02 | II | Calcium chloride Solution for Intravenous Injection | Lack of Assurance of Sterility |
| 2023-10-02 | II | Lidocaine HCl 4% ophthalmic solution | Lack of Assurance of Sterility |
| 2023-10-02 | II | Moxifloxacin in Balanced Salt Solution | Lack of Assurance of Sterility |
| 2023-10-02 | II | TPC Drops (tropicamide 1%- phenylephrine 2.5%- cyclopentolate HCl 1% o | Lack of Assurance of Sterility |
| 2023-10-02 | II | Calcium Gluconate Ophthalmic Irrigation Solution 1% | Lack of Assurance of Sterility |
The table shows 8 of the 24 recalls; the rest are in FDA’s enforcement reports.
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
2 of the 100 facilities on FDA’s list are in New York. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Form FDA 483, inspection of Pine Pharmaceuticals, LLC, 11/4/2025 to 11/14/2025. fda.gov
- FDA. Drug recall enforcement reports for Pine Pharmaceuticals, LLC, read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider